The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that strengthens its position in the precision diagnostics sector, Plus Therapeutics announced that its Houston-based clinical laboratory, CNSide Diagnostics, has received accreditation from the College of American Pathologists (CAP). This accreditation follows a rigorous inspection of laboratory protocols and quality standards, representing a significant regulatory milestone for its diagnostic platform. According to reports, the market reacted positively to the news, with shares of the Nasdaq-listed company rising 8.7% to $5.89.
The CAP accreditation is widely regarded as the "gold standard" in laboratory quality assurance, complementing the company's existing CLIA certification to support the U.S. commercial expansion of the CNSide platform. Per market data, the company reported a net loss of $6.9 million for the first quarter of 2026, a significant improvement from the $17.4 million loss in the same period last year (Investing.com). The company also held cash and investments totaling $15.1 million as of March 31, 2026, providing an operational runway to advance its clinical programs.
Sign in to access this content
Sign InInvestors should watch the stock's performance following its close at $5.915 on June 4, 2026, as it tests resistance levels near its recent highs. Looking at the economic calendar, there are no direct corporate events scheduled for the next seven days, but focus remains on the upcoming REYOBIQ clinical trial data expected in Q3 2026 as a major catalyst. Additionally, the company is targeting insurance coverage for 150 million lives in the U.S. by the end of the year.